MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1056/nejmoa2604166

Медицинская библиотека · The New England journal of medicine · 2026

Blinatumomab for Replacing Chemotherapy in Pediatric Acute Lymphoblastic Leukemia.

Schrappe Martin, Locatelli Franco, Valsecchi Maria Grazia, Zugmaier Gerhard, Vossen-Gajcy Michaela, Starý Jan, Attarbaschi Andishe, Möricke Anja, Bourquin Jean-Pierre, Barbaric Draga, Elitzur Sarah, Silvestri Daniela, Kolenova Alexandra, Dalla-Pozza Luciano, Bodmer Nicole, Stanulla Martin, Alten Julia, Zaman Faraz, Bergmann Anke, Cazzaniga Giovanni, Brüggemann Monika, Buldini Barbara, Köhler Rolf, Fazio Grazia, Rössig Claudia, Sramkova Lucie, Parasole Rosanna, Hundsdörfer Patrick, Putti Maria Caterina, Borkhardt Arndt, Fagioli Franca, Bettini Laura Rachele, Poyer Fiona, von Stackelberg Arend, Vinti Luciana, Conter Valentino, Zimmermann Martin, Rizzari Carmelo, Cario Gunnar, Biondi Andrea, AIEOP-BFM ALL 2017 Consortium

СтатьяРандомизированное исследованиеМногоцентровое исследованиеКлиническое исследование III фазыПеревод в очереди

Аннотация

BACKGROUND

Blinatumomab, a bispecific T-cell engager targeting the CD19 antigen on B cells, may offer an option to safely replace cycles of traditional chemotherapy in pediatric patients with newly diagnosed high-risk B-cell acute lymphoblastic leukemia (ALL).

METHODS

We randomly assigned, in a 1:1 ratio, children with high-risk B-cell ALL to receive two cycles of blinatumomab (blinatumomab group) or two cycles of chemotherapy (control group) after consolidation. The primary end point was event-free survival as evaluated in a time-to-event analysis; the duration of event-free survival was defined as the time from randomization to the first event among resistance to protocol treatment, relapse, second cancer, or death from any cause. Our primary objective was to evaluate whether the 4-year event-free survival would be 10 percentage points higher in the blinatumomab group than in the control group.

RESULTS

Overall, 709 of 768 eligible patients (92.3%) underwent randomization; 358 were assigned to the blinatumomab group and 351 to the control group. A planned interim analysis at a median follow-up of 2.9 years showed an estimated 4-year event-free survival of 83.0% (95% confidence interval [CI], 77.4 to 87.4) in the blinatumomab group and 70.3% (95% CI, 63.8 to 75.9) in the control group (P = 0.0002 in an intention-to-treat analysis). The estimated hazard ratio for a primary end-point event (blinatumomab vs. control) was 0.51 (95% CI, 0.35 to 0.73) as assessed with a Cox model. Infection related to the trial treatment occurred in 23.9% of patients in the blinatumomab group and in 69.4% of those in the control group (P<0.001). Life-threatening adverse events occurred in 2 patients (0.5%) in the blinatumomab group, including one (in 0.3%) that was fatal, and in 16 patients (4.7%) in the control group. Neurotoxic events were reported in 12.0% and 3.2%, respectively (P<0.001). Cytokine release syndrome of grade 2 or higher occurred in 1.1% of patients in the blinatumomab group.

CONCLUSIONS

In children with newly diagnosed high-risk B-cell ALL, replacement of two cycles of highly toxic conventional chemotherapy with blinatumomab resulted in a significantly greater percentage of patients with event-free survival at 4 years. (Funded by Deutsche Krebshilfe and others; AIEOP-BFM ALL 2017 EudraCT number, 2016-001935-12; EU Clinical Trials number, 2023-509856-32-00; and ClinicalTrials.gov number, NCT03643276.).

Для цитирования: Schrappe Martin, Locatelli Franco, Valsecchi Maria Grazia, Zugmaier Gerhard, Vossen-Gajcy Michaela, Starý Jan, Attarbaschi Andishe, Möricke Anja, Bourquin Jean-Pierre, Barbaric Draga, Elitzur Sarah, Silvestri Daniela, Kolenova Alexandra, Dalla-Pozza Luciano, Bodmer Nicole, Stanulla Martin, Alten Julia, Zaman Faraz, Bergmann Anke, Cazzaniga Giovanni, Brüggemann Monika, Buldini Barbara, Köhler Rolf, Fazio Grazia, Rössig Claudia, Sramkova Lucie, Parasole Rosanna, Hundsdörfer Patrick, Putti Maria Caterina, Borkhardt Arndt, Fagioli Franca, Bettini Laura Rachele, Poyer Fiona, von Stackelberg Arend, Vinti Luciana, Conter Valentino, Zimmermann Martin, Rizzari Carmelo, Cario Gunnar, Biondi Andrea, AIEOP-BFM ALL 2017 Consortium. Blinatumomab for Replacing Chemotherapy in Pediatric Acute Lymphoblastic Leukemia.. The New England journal of medicine. 2026. DOI: 10.1056/nejmoa2604166.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.